Myotonic dystrophy (DM)
Abstract
Myotonic dystrophy (DM) is associated with the expansion and instability of a trinucleotide (CTG) repeat at the DM locus on chromosome 19 . Direct genomic analysis in the German population was carried out on 18 DM families, six families with equivocal diagnosis, 69 subjects with equivocal clinical diagnosis, and 100 controls using the polymerase chain reaction (PCR) and a refined Southern protocol.
In the majority of the cases molecular analysis confirmed the clinical diagnosis. These included seven cases of congenital DM (CDM) with widely differing gene expansions and instabilities. In most DM families the expanded fragment became larger in successive generations, but we also identified four families with contractions and two families that showed stability of the enlarged fragment during transmission.
In four clinically defined DM patients we were unable to detect enlarged CTG repeats. Sequencing of each exon of the DM gene in two of these patients failed to show any mutations.
Our cases have important implications for genetic counselling of DM families, highlighting both the diagnostic value of direct genomic analysis and its limitations.
(JMed Genet 1995;32:645-649) DM, also known as Curschmann-Steinert disease, is an autosomal dominant disorder and the most frequent form of adult muscular dystrophy with a minimal incidence of 1 in 8000 in the European population.' The penetrance is high and new mutations are rare. The clinical picture varies within and between families. Common symptoms are progressive muscle weakness, wasting, and myotonia characterising DM as a neuromuscular disease. However, a variety of other systems can be involved and symptoms include cataracts, cardiac arrhythmias, smooth muscle involvement, brain alterations, hypersomnia, and abnormal glucose response.' In males, premature frontal balding and testicular atrophy may be present and in females ovarian insufficiency and many other symptoms may be detectable.' Anticipation, the phenomenon in which symptom severity increases and age of symptom onset falls in succeeding generations of a disease pedigree, is a characteristic feature of DM.W DM is caused by the expansion and instability of a CTG trinucleotide repeat in the 3' untranslated region of a gene at 1 9q13.2-13.3, encoding a putative cAMP dependent protein kinase (DMPK). 3 In the normal population the CTG copy number ranges from five to about 37,4 but in DM patients there are extreme expansions up to 4000 copies.5 There are no reports of the normal range overlapping with the minimal repeat number associated with the DM phenotype. There is a broad correlation of symptom severity with expansion size, although this is more readily observable within rather than between pedigrees. 6 In the majority of reported cases the CTG expansion increases in size with transmission in a DM pedigree. This may act as a molecular basis for anticipation,2 greater expansion sizes being generally associated with increasing symptom severity.6 However, there are a number of reports of contraction of the repeat upon transmission, mainly paternally.5'0 It is also possible that stable transmissions of relatively small expansions are underestimated owing to ascertainment biases."
The amplified CTG repeat region shows both meiotic and mitotic instability. The somatic mosaicism resulting from mitotic instability is characterised by a diffuse smear of fragments harbouring expanded repeats, occurring at least in blood leucocytes generally used for DNA extraction,12-14 whereas the differences in size within one generation of a DM family may be explained by meiotic instability of germline mosaicism.
Materials and methods

DNA ANALYSIS
Genomic DNA was isolated from peripheral blood samples according to Miller et Direct molecular analysis of myotonic dystrophy in the Gernan population In families 17 and 18 there was considerable overlap of the ranges of the expansions in the affected family members and it was not possible to show a clear trend in the behaviour of the expansion in these pedigrees. Clinical anticipation was apparent in family 17 , where the father has classical DM with myotonia (only detectable by EMG) and an age at onset of approximately 40 years. The son, shown in table 3B, has remarkable myotonic discharges on EMG and began presenting with classical DM symptoms at the age of 17 years.
Owing to small family sizes we were unable to investigate multiple transmission events in these pedigrees. It is therefore unclear if the predominant transmission of contractions/ stable expansions to sons is simply an artefact of our data.
There were no examples in our families of contractions from the pathological back into the normal range.
ANALYSIS OF EQUIVOCAL CASES
In six families in which DM had been suggested on clinical grounds no expansions of the CTG repeat could be shown at the molecular level. As a consequence the families were reanalysed clinically and alternative diagnoses were made, including Peno-Shokeir syndrome I (arthrogryposis multiplex congenita) and congenital myopathy associated with malignant hyperthermia.
In certain cases we had access only to blood samples from subjects with suspected DM; no samples were available from other family members. There were 69 such patients, of whom 35 had been "definitely" diagnosed with DM, and for the remaining 34 the clinical diagnosis was equivocal. In the "equivocal" group the DM diagnosis was confirmed for five (14-7%) of these patients. In the remaining patients in this group other diagnoses were reached by the clinicians after receipt of this molecular information. In the "definite" group the diagnosis was confirmed in 31 patients (88-6%). However, in the remaining four patients two normal CTG alleles were present, yet clinical reassessment after the molecular analysis still indicated DM as the most appropriate diagnosis. Clinical data for two of these four "non-expansion DM" patients are presented in table 4. Each exon of the DMPK gene was sequenced in these two patients but no mutations were detected.
Discussion
This study confirms and extends previous observations on both the normal and expanded DM alleles, focusing exclusively on the German population. It confirms previous reports that contraction of the repeat is a much more common phenomenon than had originally been expected,5 6-10 although in this case the numbers are too small to confirm the apparent male bias in this effect.
The data reported here clearly show that the correlation between expansion size and symptom severity is broad rather than absolute, illustrating the difficulties which surround not only prenatal diagnosis but also predictive estimation of disease severity based on expansion size. At its most extreme form transmission of a contracted allele was associated with clinical presentation with CDM, a phenomenon which has only been reported once previously, when an 8 kb expansion in a classically affected mother was transmitted as a 4 kb expansion to a congenitally affected child. 9 The implications of this finding, particularly for prenatal diagnosis, cannot be overstressed.
It is interesting that in all reported cases in which biopsy material has been analysed larger expansions have always been found in the muscle tissue than the blood of affected subjects.2 22 It was unexpected that in four of our cases in which two normal alleles were identified at the DM locus there remained a clinically definite diagnosis of DM. As shown in table 4 these fulfil all recognised criteria for diagnosis of DM, and this remained the most appropriate clinical assessment at the point of examination. It is possible, however, that these patients may represent cases related to the recently described PROMM syndrome,24 although in the absence ofa known mutation(s) underlying this disorder this hypothesis cannot be tested. The possibility also remains that these patients may represent a form of allelic heterogeneity for DM. In the fragile X syndrome of mental retardation, another of the trinucleotide repeat disorders, a case has been reported in which a point mutation within the FMR1 gene resulted in a phenotype identical to that caused by the trinucleotide expansion.25 However, in the patients presented here exonic sequencing of the entire DMPK gene failed to identify any mutations. Although we have not formally excluded the possibility of an abnormal intronic splice site mutation in these patients, our data suggest that mutations within the DMPK gene itself are unlikely to be the cause of a significant number of cases of clinical DM in which there is no CTG expansion. We are currently attempting to identify genes which are closely related to DMPK at the DNA sequencing level, and these will be analysed as potential candidates for these cases and PROMM-like patients. It will also be important to confirm that these patients do not represent somatic mosaics, in whom there has been an expansion of the CTG repeat in the affected tissues.
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